News Nxera Pharma Co., Ltd. OTC Markets

Equities

SOLTF

JP3431300007

Market Closed - OTC Markets Other stock markets 09:50:04 20/06/2024 pm IST			5-day change	1st Jan Change
9.43 ^USD	-5.70%		-5.70%	-5.70%

31/05	Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	MT
30/05	Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	04:35am	AQ
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023	18/06	AQ
Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	31/05	MT
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05	AQ
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05	AQ
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05	CI
Nxera Pharma Co., Ltd. and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05	CI
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	10/05	AQ
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	09/05	AQ
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024	09/05	AQ
Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18/04	MT
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	17/04	AQ
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17/04	MT
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04	AQ
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04	CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16/04	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	15/04	AQ
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	15/04	CI
Nxera Pharma joins the World Orphan Drug Alliance	08/04	AQ
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC	03/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nxera Pharma Co., Ltd. OTC Markets

Equities

SOLTF

JP3431300007

Summary

Filters